Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds

References

• Shen Z. Genomic instability and cancer: an introduction. J Mol Cell Biol. 2011;3:1–3.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649.
   PubMed Web of Science ®Google Scholar
• Yao Y, Dai W. Genomic instability and cancer. J Carcinog Mutagen. 2014;5:1000165.
   Google Scholar
• Nasmyth K. Segregating sister genomes: the molecular biology of chromosome separation. Science. 2002;297:559–565.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–265.
   PubMed Web of Science ®Google Scholar
• Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem-Anti-Cancer Agents. 2005;5:65–71.
   PubMedGoogle Scholar
• Gotta M. Cell division machinery and disease. New York, NY: Springer Science+Business Media; 2017.
   Google Scholar
• Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086–2095.
   PubMed Web of Science ®Google Scholar
• Hall A. The cytoskeleton and cancer. Cancer Metast Rev. 2009;28:5–14.
   PubMed Web of Science ®Google Scholar
• Kampan NC, Madondo MT, McNally OM, et al. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015:413076.
   PubMed Web of Science ®Google Scholar
• Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193–203.
   PubMed Web of Science ®Google Scholar
• Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849.
   PubMed Web of Science ®Google Scholar
• Mavroeidis L, Sheldon H, Briasoulis E, et al. Metronomic vinorelbine: anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol. 2015;47:455–464.
   PubMed Web of Science ®Google Scholar
• Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–3559.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–1277.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ianniello GP, Maiorino L, et al. Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial. Lung Cancer. 1998;21:S33–S34.
   Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–372.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–3663.
   PubMed Web of Science ®Google Scholar
• Camerini A, Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
   PubMed Web of Science ®Google Scholar
• Kontopodis E, Hatzidaki D, Varthalitis I, et al. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic oncology research group. J Chemother. 2013;25:49–55.
   PubMed Web of Science ®Google Scholar
• Mencoboni M, Filiberti RA, Taveggia P, et al. Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC. Anticancer Res. 2017;37:3189–3194.
   PubMed Web of Science ®Google Scholar
• Tan EH, Tan DSW, Li WY, et al. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer. 2015;88:289–296.
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360–367.
   PubMed Web of Science ®Google Scholar
• Treat J, Scagliotti GV, Peng G, et al. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. Lung Cancer. 2012;76:222–227.
   PubMed Web of Science ®Google Scholar
• Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12:1232–1237.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103.
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 2000;18:2354–2362.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–673.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–155.
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol. 2007;2:939–946.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.
   PubMed Web of Science ®Google Scholar
• Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1074–1080.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:3390–3399.
   PubMed Web of Science ®Google Scholar
• Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern cooperative oncology group trial. J Clin Oncol. 2000;18:623–631.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190–196.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster J-P, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–1088.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30:2055–2062.
   PubMed Web of Science ®Google Scholar
• George B, Kelly K, Ko A, et al. P1.46: phase I study of Nivolumab + Nab-paclitaxel in solid tumors: preliminary analysis of the non-small cell lung cancer cohort: track: advanced NSCLC. J Thorac Oncol. 2016;11:S211–S212.
   Web of Science ®Google Scholar
• Cappuzzo F, McCleod M, Hussein M, et al. LBA53IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018; 29(8).
   Web of Science ®Google Scholar
• Socinski MA, Rittmeyer A, Shapovalov D, et al. LBA65IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. Ann Oncol. 2018; 29(8).
   Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379:2040–2051.
   PubMed Web of Science ®Google Scholar
• Swami U, Shah U, Goel S. Eribulin in non-small cell lung cancer: challenges and potential strategies. Expert Opin Investig Drugs. 2017;26:495–508.
   PubMed Web of Science ®Google Scholar
• Cortes J, Schöffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: emerging data and clinical implications. Cancer Treat Rev. 2018;70:190–198.
   PubMed Web of Science ®Google Scholar
• Spira AI, Iannotti NO, Savin MA, et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non–small-cell lung cancer. Clin Lung Cancer. 2012;13:31–38.
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Tsao-Wei DD, Groshen S, et al. A phase II study of halichondrin B analogue eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012;7:574–578.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Aisner J, Kumar K, et al. Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC). Jco. 2013;31:e19145–e19145.
   Google Scholar
• Mok TS, Geater SL, Iannotti N, et al. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Ann Oncol. 2014;25:1578–1584.
   PubMed Web of Science ®Google Scholar
• Waller CF, Vynnychenko I, Bondarenko I, et al. An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non–small-cell lung cancer. Clin Lung Cancer. 2015;16:92–99.
   PubMed Web of Science ®Google Scholar
• Katakami N, Felip E, Spigel DR, et al. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017;28:2241–2247.
   PubMedGoogle Scholar
• Nanda R, Wilks S, Modiano MR, et al. Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC). Jco. 2015;33:e12070–e12070.
   Web of Science ®Google Scholar
• Azarenko O, Smiyun G, Mah J, et al. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Mol Cancer Ther. 2014;13:2092–2103.
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Matikas A, Koinis F, et al. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. Br J Cancer. 2016;115:784–788.
   PubMed Web of Science ®Google Scholar
• Madan A, Jones BS, Bordoni R, et al. Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients. Cancer Chemother Pharmacol. 2016;78:509–515.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Shvartsbeyn M. Epothilones in development for non–small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer. 2012;13:171–180.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Lara PN, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non–small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Jco. 2007;25:3448–3455.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Anthony Greco F, Waterhouse DM, et al. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer. 2012;78:70–75.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Schneider C-P, Tsai C-M, et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol. 2013;31:1990–1996.
   PubMed Web of Science ®Google Scholar
• Nayak L, DeAngelis LM, Robins HI, et al. Multi-center phase II study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015;121:4165–4172.
   PubMed Web of Science ®Google Scholar
• Lam ET, Goel S, Schaaf LJ, et al. Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol [Internet]. 2012;69(2):523–531.
   Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29:2943–2971.
   PubMed Web of Science ®Google Scholar
• Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a Novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006;12:2834–2840.
   PubMed Web of Science ®Google Scholar
• Eliopoulos H, Gabrail N, Coates A, et al. P2-251: phase 1/2 study evaluating the safety and efficacy of ABT-751 in combination with docetaxel vs docetaxel alone in subjects with advanced or metastatic non-small-cell lung cancer. J Thorac Oncol. 2007;2:S672.
   Google Scholar
• Ma T, Fuld AD, Rigas JR, et al. A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy. 2012;58:321–329.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Mauer A, Smakal M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2011;29:1075–1082.
   PubMed Web of Science ®Google Scholar
• Mauer AM, Cohen EEW, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:631–636.
   PubMed Web of Science ®Google Scholar
• Nicholson B, Lloyd G, Miller B, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006;17:25–31.
   PubMed Web of Science ®Google Scholar
• Millward M, Mainwaring P, Mita A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs. 2012;30:1065–1073.
   PubMed Web of Science ®Google Scholar
• Heist RS, Aren OR, Mita AC, et al. Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Jco. 2014;32:8054–8055.
   Google Scholar
• Lloyd GK, Mueller P, Zippelius A, et al. Abstract A07: plinabulin: evidence for an immune-mediated mechanism of action. Cancer Res. 2016;76:A07–A07.
   PubMed Web of Science ®Google Scholar
• Ma R, Yang B, Wu C. A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells. Int Immunopharmacol. 2008;8:1408–1417.
   PubMed Web of Science ®Google Scholar
• Mohanlal RW, LLoyd K, Huang L. Plinabulin, a novel small molecule clinical stage IO agent with anti-cancer activity, to prevent chemo-induced neutropenia and immune related AEs. Jco. 2018;36:126–127.
   Web of Science ®Google Scholar
• Boehle AS, Sipos B, Kliche U, et al. Combretastatin A-4 prodrug inhibits growth of human non–small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg. 2001;71:1657–1665.
   PubMed Web of Science ®Google Scholar
• Ng Q-S, Mandeville H, Goh V, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol. 2012;23:231–237.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Martin M, Bouchet BP, et al. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. BMC Cancer. 2018;18.
   PubMed Web of Science ®Google Scholar
• Elez E, Gomez-Roca C, Soto Matos-Pita A, et al. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. Invest New Drugs. 2018.
   PubMedGoogle Scholar
• Blayney D, Ogenstad S, Shi Y, et al. P1.01-06 plinabulin, a novel immuno-oncology agent mitigates docetaxel chemotherapy -induced-neutropenia and -thrombocytopenia in NSCLC patients. J Thorac Oncol. 2018;13:S461.
   Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017;28:iv1–iv21.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non–small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16:807–821.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2018;29:iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Sandler A, Schiller JH, Johnson DH. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;;355(24):2542-2550.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078–2092.
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Stinchcombe TE, Fried DB, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;2:845–853.
   PubMed Web of Science ®Google Scholar
• Sörenson S, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol. 2001;40:327–339.
   PubMed Web of Science ®Google Scholar
• Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17:286–301.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Recently updated NCCN clinical practice guidelines in oncologyTM. Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx.
   Google Scholar
• Ferrara R, Pilotto S, Peretti U, et al. Tubulin inhibitors in non-small cell lung cancer: looking back and forward. Expert Opin Pharmacother. 2016;17:1113–1129.
   PubMed Web of Science ®Google Scholar
• Hardin C, Shum E, Singh A, et al. Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. Expert Opin Pharmacother. 2017;18:701–716.
   PubMed Web of Science ®Google Scholar
• Calinescu -A-A, Castro MG. Microtubule targeting agents in glioma. Transl Cancer Res. 2016;5:S54-S60–S60.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implicationsfor cancer treatment. Curr Cancer Drug Targets. 2007;7:566–581.
   PubMed Web of Science ®Google Scholar
• André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11:413–431.
   PubMed Web of Science ®Google Scholar
• Manegold C, Dingemans A-MC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12:194–207.
   PubMed Web of Science ®Google Scholar
• Zhang H-L, Ruan L, Zheng L-M, et al. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer. 2012;77:9–15.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Luo X-P, Xian L. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014 [cited 2019 Feb 28];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976369/
   Web of Science ®Google Scholar
• Bertino EM, Williams TM, Nana-Sinkam SP, et al. Stromal caveolin-1 is associated with response and survival in a phase II trial of nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin Lung Cancer. 2015;16:466–474.
   PubMed Web of Science ®Google Scholar